- 询价
- Nebulabio
- 中国
- NBAB-195068
- 2026年01月07日
- ELISA
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant Human metapneumovirus F/Fusion Protein Protein
- 形态：
liquid
- 保质期：
见COA
- 库存：
大量
- 供应商：
北京辰辉创聚生物技术有限公司
- 应用范围：
ELISA
- 靶点：
Human metapneumovirus F/Fusion
- 抗体英文名：
Anti-HMPV F/Fusion Protein Antibody
- 抗体名：
抗HMPV F/Fusion Protein抗体
- 规格：
100ul; 500ul; 1ml
| 产品信息
品名：NebuSelect™ Anti-HMPV F/Fusion Protein Antibody
别名：Fusion glycoprotein F0, Protein F, Fusion glycoprotein F2, Fusion glycoprotein F1, F
货号：NBAB-195068
品牌：Nebulabio
规格：100ul; 500ul; 1ml
| 产品描述
NebuSelect™ Anti-HMPV F/Fusion Protein Antibody (CAT# NBAB-195068) is produced in mammalian expression systems and exhibits specificity for Human metapneumovirus F/Fusion Protein. This antibody is validated for ELISA.
| 产品属性
Product Category：Recombinant Antibody
Reactivity：Human metapneumovirus
Specificity：Human metapneumovirus F/Fusion Protein
Immunogen：Recombinant Human metapneumovirus F/Fusion Protein Protein
Isotype：Monoclonal Human IgG
Purification：Monoclonal Human IgG
Buffer：0.2 μm filtered solution in PBS, pH7.4, containing 0.09% Sodium azide, 50% glycerol.
Conjugate：Unconjugated
Applications：ELISA
Dilution：ELISA 1:2000～1:10000
Storage：This liquid antibody can be stored at 2℃-8℃ for at least two weeks. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20℃. When reconstituted in sterile pH 7.4 0.01M PBS or antibody diluent, the antibody is stable for at least two weeks at 2-4℃.
For Research Use Only!
To get more information, please contact us freely.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验BioID: A Screen for Protein‐Protein Interactions
, or see recipe ) Quenching solution (see recipe ) Antibodies specific to BioID fusion protein (e.g., anti‐myc/HA) or chicken
Protein Microarrays for Identification of Novel Extracellular Protein‐Protein Interactions
, and analysis. A protocol is described for enhanced detection of low?affinity interactions by generating multivalent complexes using Fc?fusion bait proteins and protein A microbeads, along with a statistical method for hit scoring and identification
on safety and efficacy. Therefore, assessment of immunogenicity of the therapeutic protein is an essential part of its clinical development. This involves testing strategies which provide relevant information on antibody responses. This chapter describes
技术资料暂无技术资料 索取技术资料
